Browse TGFBR1

Summary
SymbolTGFBR1
Nametransforming growth factor, beta receptor 1
Aliases ALK-5; activin A receptor type II-like kinase, 53kDa; MSSE; ESS1; transforming growth factor, beta receptor ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Cell junction, tight junction Cell surface Membrane raft
Domain PF01064 Activin types I and II receptor domain
PF00069 Protein kinase domain
PF08515 Transforming growth factor beta type I GS-motif
Function

Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.

> Gene Ontology
 
Biological Process GO:0000186 activation of MAPKK activity
GO:0001501 skeletal system development
GO:0001525 angiogenesis
GO:0001558 regulation of cell growth
GO:0001654 eye development
GO:0001655 urogenital system development
GO:0001667 ameboidal-type cell migration
GO:0001701 in utero embryonic development
GO:0001822 kidney development
GO:0001824 blastocyst development
GO:0001837 epithelial to mesenchymal transition
GO:0001935 endothelial cell proliferation
GO:0001936 regulation of endothelial cell proliferation
GO:0001937 negative regulation of endothelial cell proliferation
GO:0001938 positive regulation of endothelial cell proliferation
GO:0002062 chondrocyte differentiation
GO:0002088 lens development in camera-type eye
GO:0003002 regionalization
GO:0003007 heart morphogenesis
GO:0003197 endocardial cushion development
GO:0003198 epithelial to mesenchymal transition involved in endocardial cushion formation
GO:0003203 endocardial cushion morphogenesis
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003208 cardiac ventricle morphogenesis
GO:0003222 ventricular trabecula myocardium morphogenesis
GO:0003223 ventricular compact myocardium morphogenesis
GO:0003229 ventricular cardiac muscle tissue development
GO:0003231 cardiac ventricle development
GO:0003272 endocardial cushion formation
GO:0003279 cardiac septum development
GO:0003281 ventricular septum development
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0007015 actin filament organization
GO:0007050 cell cycle arrest
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007184 SMAD protein import into nucleus
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0007548 sex differentiation
GO:0008354 germ cell migration
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0009791 post-embryonic development
GO:0009952 anterior/posterior pattern specification
GO:0010631 epithelial cell migration
GO:0010717 regulation of epithelial to mesenchymal transition
GO:0010718 positive regulation of epithelial to mesenchymal transition
GO:0010862 positive regulation of pathway-restricted SMAD protein phosphorylation
GO:0014706 striated muscle tissue development
GO:0014855 striated muscle cell proliferation
GO:0016049 cell growth
GO:0016202 regulation of striated muscle tissue development
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0017038 protein import
GO:0018105 peptidyl-serine phosphorylation
GO:0018107 peptidyl-threonine phosphorylation
GO:0018209 peptidyl-serine modification
GO:0018210 peptidyl-threonine modification
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030031 cell projection assembly
GO:0030038 contractile actin filament bundle assembly
GO:0030198 extracellular matrix organization
GO:0030199 collagen fibril organization
GO:0030307 positive regulation of cell growth
GO:0030335 positive regulation of cell migration
GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway
GO:0031032 actomyosin structure organization
GO:0031346 positive regulation of cell projection organization
GO:0031396 regulation of protein ubiquitination
GO:0032147 activation of protein kinase activity
GO:0032231 regulation of actin filament bundle assembly
GO:0032233 positive regulation of actin filament bundle assembly
GO:0032330 regulation of chondrocyte differentiation
GO:0032331 negative regulation of chondrocyte differentiation
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032924 activin receptor signaling pathway
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033002 muscle cell proliferation
GO:0033157 regulation of intracellular protein transport
GO:0033674 positive regulation of kinase activity
GO:0034330 cell junction organization
GO:0034504 protein localization to nucleus
GO:0035265 organ growth
GO:0035270 endocrine system development
GO:0036314 response to sterol
GO:0040017 positive regulation of locomotion
GO:0042118 endothelial cell activation
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0043010 camera-type eye development
GO:0043062 extracellular structure organization
GO:0043149 stress fiber assembly
GO:0043393 regulation of protein binding
GO:0043405 regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043491 protein kinase B signaling
GO:0043542 endothelial cell migration
GO:0044089 positive regulation of cellular component biogenesis
GO:0044744 protein targeting to nucleus
GO:0045137 development of primary sexual characteristics
GO:0045165 cell fate commitment
GO:0045216 cell-cell junction organization
GO:0045786 negative regulation of cell cycle
GO:0045860 positive regulation of protein kinase activity
GO:0045927 positive regulation of growth
GO:0046546 development of primary male sexual characteristics
GO:0046620 regulation of organ growth
GO:0046661 male sex differentiation
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0046847 filopodium assembly
GO:0048514 blood vessel morphogenesis
GO:0048538 thymus development
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048634 regulation of muscle organ development
GO:0048638 regulation of developmental growth
GO:0048644 muscle organ morphogenesis
GO:0048663 neuron fate commitment
GO:0048701 embryonic cranial skeleton morphogenesis
GO:0048704 embryonic skeletal system morphogenesis
GO:0048705 skeletal system morphogenesis
GO:0048706 embryonic skeletal system development
GO:0048732 gland development
GO:0048738 cardiac muscle tissue development
GO:0048762 mesenchymal cell differentiation
GO:0048844 artery morphogenesis
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0051017 actin filament bundle assembly
GO:0051098 regulation of binding
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051216 cartilage development
GO:0051222 positive regulation of protein transport
GO:0051272 positive regulation of cellular component movement
GO:0051489 regulation of filopodium assembly
GO:0051491 positive regulation of filopodium assembly
GO:0051492 regulation of stress fiber assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051496 positive regulation of stress fiber assembly
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0055008 cardiac muscle tissue morphogenesis
GO:0055010 ventricular cardiac muscle tissue morphogenesis
GO:0055017 cardiac muscle tissue growth
GO:0055021 regulation of cardiac muscle tissue growth
GO:0055024 regulation of cardiac muscle tissue development
GO:0060017 parathyroid gland development
GO:0060021 palate development
GO:0060037 pharyngeal system development
GO:0060038 cardiac muscle cell proliferation
GO:0060043 regulation of cardiac muscle cell proliferation
GO:0060317 cardiac epithelial to mesenchymal transition
GO:0060389 pathway-restricted SMAD protein phosphorylation
GO:0060390 regulation of SMAD protein import into nucleus
GO:0060391 positive regulation of SMAD protein import into nucleus
GO:0060393 regulation of pathway-restricted SMAD protein phosphorylation
GO:0060411 cardiac septum morphogenesis
GO:0060412 ventricular septum morphogenesis
GO:0060415 muscle tissue morphogenesis
GO:0060419 heart growth
GO:0060420 regulation of heart growth
GO:0060485 mesenchyme development
GO:0060491 regulation of cell projection assembly
GO:0060537 muscle tissue development
GO:0060840 artery development
GO:0060976 coronary vasculature development
GO:0060977 coronary vasculature morphogenesis
GO:0060978 angiogenesis involved in coronary vascular morphogenesis
GO:0060982 coronary artery morphogenesis
GO:0061035 regulation of cartilage development
GO:0061037 negative regulation of cartilage development
GO:0061383 trabecula morphogenesis
GO:0061384 heart trabecula morphogenesis
GO:0061448 connective tissue development
GO:0061458 reproductive system development
GO:0061572 actin filament bundle organization
GO:0070723 response to cholesterol
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0072001 renal system development
GO:0072132 mesenchyme morphogenesis
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:0090316 positive regulation of intracellular protein transport
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097305 response to alcohol
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1901861 regulation of muscle tissue development
GO:1902593 single-organism nuclear import
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903533 regulation of protein targeting
GO:1903829 positive regulation of cellular protein localization
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904888 cranial skeletal system development
GO:1904951 positive regulation of establishment of protein localization
GO:1905005 regulation of epithelial to mesenchymal transition involved in endocardial cushion formation
GO:1905007 positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation
GO:1905071 occluding junction disassembly
GO:1905073 regulation of occluding junction disassembly
GO:1905075 positive regulation of occluding junction disassembly
GO:1905223 epicardium morphogenesis
GO:2000027 regulation of organ morphogenesis
GO:2000147 positive regulation of cell motility
GO:2000826 regulation of heart morphogenesis
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001235 positive regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004675 transmembrane receptor protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0005024 transforming growth factor beta-activated receptor activity
GO:0005025 transforming growth factor beta receptor activity, type I
GO:0005057 receptor signaling protein activity
GO:0005114 type II transforming growth factor beta receptor binding
GO:0005126 cytokine receptor binding
GO:0005160 transforming growth factor beta receptor binding
GO:0019199 transmembrane receptor protein kinase activity
GO:0019838 growth factor binding
GO:0019955 cytokine binding
GO:0046332 SMAD binding
GO:0050431 transforming growth factor beta binding
GO:0070411 I-SMAD binding
Cellular Component GO:0005923 bicellular tight junction
GO:0043235 receptor complex
GO:0043296 apical junction complex
GO:0045121 membrane raft
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0070022 transforming growth factor beta receptor homodimeric complex
GO:0070160 occluding junction
GO:0098589 membrane region
GO:0098802 plasma membrane receptor complex
GO:0098857 membrane microdomain
GO:1902554 serine/threonine protein kinase complex
GO:1902911 protein kinase complex
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04068 FoxO signaling pathway
hsa04144 Endocytosis
hsa04350 TGF-beta signaling pathway
hsa04380 Osteoclast differentiation
hsa04390 Hippo signaling pathway
hsa04520 Adherens junction
Reactome R-HSA-5688426: Deubiquitination
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-2173788: Downregulation of TGF-beta receptor signaling
R-HSA-3304349: Loss of Function of SMAD2/3 in Cancer
R-HSA-3656534: Loss of Function of TGFBR1 in Cancer
R-HSA-3642278: Loss of Function of TGFBR2 in Cancer
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-3315487: SMAD2/3 MH2 Domain Mutants in Cancer
R-HSA-3304356: SMAD2/3 Phosphorylation Motif Mutants in Cancer
R-HSA-162582: Signal Transduction
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-3304351: Signaling by TGF-beta Receptor Complex in Cancer
R-HSA-2173789: TGF-beta receptor signaling activates SMADs
R-HSA-2173791: TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
R-HSA-3656532: TGFBR1 KD Mutants in Cancer
R-HSA-3656535: TGFBR1 LBD Mutants in Cancer
R-HSA-3645790: TGFBR2 Kinase Domain Mutants in Cancer
R-HSA-5689603: UCH proteinases
R-HSA-5689880: Ub-specific processing proteases
Summary
SymbolTGFBR1
Nametransforming growth factor, beta receptor 1
Aliases ALK-5; activin A receptor type II-like kinase, 53kDa; MSSE; ESS1; transforming growth factor, beta receptor ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TGFBR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TGFBR1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25924065Prostate CarcinomaInhibit immunity (T cell function)The crucial immunosuppressive B cells are plasmocytes that express IgA, interleukin (IL)-10 and programmed death ligand 1 (PD-L1), the appearance of which depends on TGFβ receptor signalling. Elimination of these cells, which also infiltrate human-therapy-resistant prostate cancer, allows CTL-dependent eradication of oxaliplatin-treated tumours.
22037217Head and Neck Squamous Cell CarcinomaInhibit immunityLoss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. However, Pten-deficient mice developed full-penetrance HNSCC in combination with type I TGF-β receptor (Tgfbr1) deletion. Molecular analysis revealed enhanced cell proliferation, decreased apoptosis, and increased expression of CCND1 in the basal layer of the head and neck epithelia, as well as in the tumors of Tgfbr1/Pten double conditional knockout (2cKO) mice.
Summary
SymbolTGFBR1
Nametransforming growth factor, beta receptor 1
Aliases ALK-5; activin A receptor type II-like kinase, 53kDa; MSSE; ESS1; transforming growth factor, beta receptor ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TGFBR1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 2 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTGFBR1
Nametransforming growth factor, beta receptor 1
Aliases ALK-5; activin A receptor type II-like kinase, 53kDa; MSSE; ESS1; transforming growth factor, beta receptor ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TGFBR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1830.559
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1810.922
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4530.751
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5560.0842
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6750.709
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4040.862
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0090.983
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0460.982
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1310.953
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6750.587
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2620.506
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0140.884
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TGFBR1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTGFBR1
Nametransforming growth factor, beta receptor 1
Aliases ALK-5; activin A receptor type II-like kinase, 53kDa; MSSE; ESS1; transforming growth factor, beta receptor ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TGFBR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTGFBR1
Nametransforming growth factor, beta receptor 1
Aliases ALK-5; activin A receptor type II-like kinase, 53kDa; MSSE; ESS1; transforming growth factor, beta receptor ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TGFBR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TGFBR1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTGFBR1
Nametransforming growth factor, beta receptor 1
Aliases ALK-5; activin A receptor type II-like kinase, 53kDa; MSSE; ESS1; transforming growth factor, beta receptor ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TGFBR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTGFBR1
Nametransforming growth factor, beta receptor 1
Aliases ALK-5; activin A receptor type II-like kinase, 53kDa; MSSE; ESS1; transforming growth factor, beta receptor ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TGFBR1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTGFBR1
Nametransforming growth factor, beta receptor 1
Aliases ALK-5; activin A receptor type II-like kinase, 53kDa; MSSE; ESS1; transforming growth factor, beta receptor ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TGFBR1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTGFBR1
Nametransforming growth factor, beta receptor 1
Aliases ALK-5; activin A receptor type II-like kinase, 53kDa; MSSE; ESS1; transforming growth factor, beta receptor ......
Chromosomal Location9q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TGFBR1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TGFBR1.
ID Name Drug Type Targets #Targets
DB039214-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)QuinolineSmall MoleculeTGFBR11
DB04434Naphthyridine InhibitorSmall MoleculeTGFBR11
DB044803-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]PyrazoleSmall MoleculeTGFBR11
DB07152N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamideSmall MoleculeTGFBR11
DB072672-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amineSmall MoleculeTGFBR11
DB08450N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amineSmall MoleculeTGFBR11